$KZR News

Kezar Life Sciences shares are trading higher after the company announced it will be acquired by Aurinia Pharmaceuticals for $6.955 in cash per share plus a contingent value right.

Kezar Life Sciences shares are trading higher after the company announced it will be acquired by Aurinia Pharmaceuticals for $6.955 in cash per share plus a contingent value right.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

Enodia Therapeutics Acquires Kezar Life Sciences Preclinical Assets For Up to $127M Plus Royalties

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

Kezar Life Sciences Granted FDA Type C Meeting In Q1 To Discuss Zetomipzomib Development And Potential Global Randomized Phase 2b Study In Relapsed And Refractory Autoimmune Hepatitis

Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Kezar Life Sciences Q3 EPS $(1.53) Beats $(2.08) Estimate

Kezar Life Sciences Announces 70% Workforce Reduction As Part Of Strategic Restructuring Plan; Estimates $6M In Restructuring Costs; Expects To Recognize Costs In Q4 2025

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

Kezar Life Sciences Announced Two Presentations From The Completed Phase 2A Portola Clinical Trial In Patients With Autoimmune Hepatitis At The Liver Meeting 2025 In Washington, DC

Kezar Life Sciences Announces Two Presentations From Completed Phase 2a PORTOLA Clinical Trial In Patients With Autoimmune Hepatitis At 2025 AASLD

Jefferies Downgrades Kezar Life Sciences to Hold, Lowers Price Target to $7

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans

William Blair Downgrades Kezar Life Sciences to Market Perform

Wells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $5

12 Health Care Stocks Moving In Friday's Pre-Market Session